Skip to Content

Brainstorm Health: Kavanaugh Vote, Hepatitis E, Lilly and Pfizer FDA Approvals

The televised hearing before the Senate Committee on the Judiciary yesterday centered on a single essential question: Did Brett Kavanaugh sexually assault Christine Blasey (now Dr. Christine Blasey Ford) at a high school party in the summer of 1982, when he was 17 years old and she was 15?

Over some three hours of questioning by a Senate interrogator, Dr. Ford made a compelling case that he did. Her testimony was raw and powerful, frighteningly vivid, and in the view of many (including me), deep-in-the-gut credible. It was nearly impossible to watch Dr. Ford’s retelling of her experience that dark night—in which she alleged that a drunken Kavanaugh held her down against her will, groped her, and put his hand over her mouth to muffle her screams—without being moved by Dr. Ford’s sheer courage in telling it. It was hard to watch Dr. Ford’s terrified, but sober testimony and not think of the millions of other women and girls who have gone through a horror just like it.

In his own hours of testimony that followed Dr. Ford’s, Kavanaugh—who is now a judge on the U.S. Court of Appeals for the D.C. Circuit—vehemently, emotionally, and angrily denied that the incident occurred or that he’d ever sexually assaulted anyone.

Though Dr. Ford identified a second man who she says was there in the room with Kavanaugh—an alleged participant in and eyewitness to this crime—the Republican mandarins presiding over the Senate inexplicably did not demand his testimony as well. Nor, inexplicably, have they called for an FBI investigation that might uncover further evidence that could help corroborate or refute Dr. Ford’s accusation.

So as to that single essential question—Did Brett Kavanaugh sexually assault Christine Blasey?—we are left without a definitive conclusion. And if the Senate does vote to elevate Judge Kavanaugh to the U.S. Supreme Court, that question will continue to ring unanswered in the minds of millions of Americans, perhaps for decades.

But then, Thursday’s testimony provoked another question as well: Does Judge Kavanaugh have the temperament to be a Justice Kavanaugh, to sit on the highest court of the land?

And that question we can answer from the evidence provided.

“The most important predictors of success on the Supreme Court, are not academic brilliance, philosophical consistency, or methodological ambition,” wrote Jeffrey Rosen, a professor at the George Washington University Law School, the president and CEO of the National Constitution Center in Philadelphia, and one of America’s most distinguished scholars of the Supreme Court. “Instead, many of the most successful Supreme Court Justices are those who get along well with their colleagues, are able to compromise, and can set aside their own ideological agendas in the interest of preserving the institutional legitimacy of the Court. By contrast, the most brilliant and philosophically ambitious Justices have often alienated their colleagues and subverted the ideals they hoped to promote.”

Court scholars refer to this ability to find common ground—to persuade through collegial argument, not polemic—as “judicial temperament.”

John Marshall, who Rosen and many others consider to be “America’s greatest Chief Justice,” was the exemplar of this. “Marshall was modest, humble, and had no airs,” wrote Rosen. “He was famously mistaken for a servant in the Richmond market when a newcomer threw him a coin and hired the Chief Justice to carry his turkey home, which Marshall did without complaint.”

That personal and philosophical modesty was also reflected in the court’s opinions during the politically explosive era of the early 19th century, when the young American republic was charting its path forward. “Marshall embodied judicial restraint, defined neutrally as a reluctance to strike down very many laws, and almost all of his decisions were readily accepted by national majorities,” Rosen writes.

The Judge Kavanaugh whom the nation witnessed yesterday, however, seemed far from this paradigm. The man who offered sworn testimony on Thursday was belligerent and fiercely partisan, blaming the committee’s obvious requirement to fairly hear Dr. Ford’s accusation on a conspiratorial plot: “Revenge on behalf of the Clintons, and millions of dollars in money from outside left-wing opposition groups,” as Judge Kavanaugh alleged.

The man who testified yesterday sounded not like a Supreme Court justice, but rather like yet another Republican member on the Senate Judiciary Committee, engaging in not only verbal combat with Democratic senators, but also—quite remarkably—seeming to threaten potential retribution: “And as we all know,” he said, “in the United States political system of the early 2000s, what goes around comes around.”

Members of the U.S. House of Representatives serve two-year terms. Presidents serve four. Senators, six. As much as Americans decry the rancorous partisanship that now defines our federal governance, the Republic can survive it. Voters have the power, after all, to cast the entire crop of elected officials out if they so choose.

But those named to the Supreme Court serve a lifetime. We can’t afford to risk giving someone that authority to change American life when he may not have the self-restraint to control his own temper.

Clifton Leaf, Editor in Chief, FORTUNE


Bipartisan report urges funding for AI research. Healthcare IT News flags a bipartisan report from the House of Representatives’ Oversight and Government Reform Subcommittee on IT centering on the need for more AI research funding. There are four main areas of emphases in the report, namely: AI’s effect on the workforce; privacy concerns; bias in algorithms; and malicious cyberattacks. You can check out the full white paper here(Healthcare IT News)


Eli Lilly, Pfizer snag FDA approvals for migraine, cancer drugs. A pair of Food and Drug Administration (FDA) victories for a pair of flagship American drug makers: Eli Lilly has won approval for the migraine medication Emgality, making it the third new migraine treatment approved this year in sudden onslaught of competition in the space (the treatment will also be provided for free to certain insured patients for a limited time). Pfizer, for its part, received the green light for Vizimpro, a drug for a rare form of lung cancer.


There’s been a human case of rat hepatitis E. Hong Kong researchers have reported the first known case of a human infection of rat hepatitis E, a strain of the virus carried by rodents. It’s still not clear how the patient contracted the virus, which is a distinct form of hepatitis E, but early theories posit it may have something to do with a rat infestation where the man lived and contaminated food. (TIME)

Walgreens to pay $34.5 million to settle SEC charges. Walgreens will pay $34.5 million to settle with Securities and Exchange Commission (SEC) charges that the company misled investors on a matter of financing related to its merger with Alliance Boots (that’s on top of penalties that two former executives, including former CEO Gregory Wasson and former CFO Wade Miquelon, who were specifically charged in the matter, will pay). The case centers on Walgreens’ framing of how likely it was to miss a stated financial goal when the Alliance Boots deal was announced. (Chicago Tribune)


Changing Earnings Rules Could Boost These Sagging Stocksby Ryan Derousseau

Facebook Data Breach Exposes 50 Million Usersby Carson Kessler

Senate Committee Advances Kavanaugh While Flake Calls for FBI Probeby Bloomberg

Elon Musk Is Learning Just Because He Thinks Something Is True Doesn’t Make It Soby Adam Lashinsky

Produced by Sy Mukherjee

Find past coverage. Sign up for other Fortune newsletters.